Evidence-Based Methodology for Obtaining Commercial Insurance Coverage of Stereotactic Radiosurgery for Intractable Epilepsy

Despite the Level I evidence supporting stereotactic radiosurgery (SRS) as an efficacious treatment for medically intractable temporal lobe epilepsy (TLE) provided by the Radiosurgery versus Open Surgery for mesial temporal lobe Epilepsy (ROSE) multicenter randomized trial (Barbaro et al., Epilepsia 2018) and the inclusion of intractable epilepsy as an appropriate indication for SRS in the ASTRO published SRS model policies, recent work has indicated that the coverage policies of the largest publicly available commercial insurers in the United States do not include coverage of SRS for intractable epilepsy (Verma et al., Practical Radiation Oncology 2019).
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research